Resource utilization in liver transplantation: Effects of patient characteristics and clinical practice

JAMA

Volumn 281, Issue 15, 1999, Pages 1381-1386

  Showstack, Jonathan ^a,i   Katz, Patricia P ^a   Lake, John R ^b,g   Brown, Robert S ^b,h   Dudley, R Adams ^a   Belle, Steven ^c   Wiesner, Russell H ^d   Zetterman, Rowen K ^e   Everhart, James ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h NONE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADULT; AGE; ALCOHOL LIVER DISEASE; ARTICLE; CLINICAL PRACTICE; COST OF ILLNESS; FEMALE; GOOD CLINICAL PRACTICE; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; LENGTH OF STAY; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; ORGAN DONOR; PRIORITY JOURNAL; RESOURCE ALLOCATION;

EID: 0033590916     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.15.1381     Document Type: Article

References (29)

1. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med. 1989;329:1014-1022, 1092-1099.
2. Lake JR. Changing indications for liver transplantation. Gastroenterol Clin North Am. 1993;22:213-229.
3. United Network for Organ Sharing. Waiting list charts by organ by ABO blood group, gender and age. UNOS Update. 1994;10:26.
4. Blue Cross/Blue Shield. The Final Report of the Task Force on Liver Transplantation in Massachusetts. Boston, Mass: Blue Cross/Blue Shield; 1983.
5. Luebs HW. Cost considerations. Semin Liver Dis. 1985;5:402-411.
6. Kankaanpaa J. Cost-effectiveness of liver transplantations: how to apply the results in resource allocation. Prev Med. 1990;19:700-704.
7. Evans RW, Manninen DL, Dong FB. An economic analysis of liver transplantation: costs, insurance coverage, and reimbursement. Gastroenterol Clin North Am. 1993;22:451-473.
8. Showstack J, Katz P, Amend W, et al. The effect of cyclosporine on the use of hospital resources for kidney transplantation. N Eng J Med. 1989;321:1086-1092.
9. Showstack J, Katz P, Amend W, Salvatierra O. The association of cyclosporine with the 1-year costs of cadaver-donor kidney transplants. JAMA. 1990;264: 1818-1823.
10. Steinbrook R. Allocating livers: devising a fair system. N Engl J Med. 1997;336:436-438.
11. Shaw BW. A collective wisdom. Liver Transpl Surg. 1997;3:680-682.
12. United Network for Organ Sharing. Amended UNOS policy 3.6: allocation of livers. World Wide Web address: http://207.87.26.13.htm. Accessed March 5, 1999.
13. Staschak S, Wagner S, Block G, et al. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. Transplant Proc. 1990;22:47-49.
14. Pageaux GP, Souche B, Perney P, et al. Results and cost of orthotopic liver transplantation for alcoholic cirrhosis. Transplant Proc 1993;25:1135-1136.
15. Wiesner RH, Porayko MK, Dickson ER, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology. 1992;16:1290-1299.
16. Lake JR, German KJ, Esquivel CO, et al. The impact of immunosuppressive regimens on the cost of liver transplantation: results from the US FK-506 multi-center trial. Transplantation. 1995;60:1089-1095.
17. Detre KM. The NIDDK liver transplantation database. In: Terasaki P, ed. Clinical Transplants, 1986. Los Angeles, Calif: UCLA Tissue Typing Laboratory; 1986:29-33.
18. Wei YL, Detre KM, Everhart JE, and the NIDDK Liver Transplantation Database. The NIDDK Liver Transplantation Database. Liver Transpl Surg. 1997; 3:10-22.
19. Katz PP, Showstack JA, Lake J, et al. Methods to estimate and analyze medical care resource use: an example from liver transplantation. Int J Technol Assess Health Care. In press.
20. Hoofnagle JH, Lombardero M, Zetterman RK, and the NIDDK Liver Transplantation Database. Donor age and outcome of liver transplantation. Hepatology. 1997;24:89-96.
21. Deschenes M, Belle SH, Krom RAF, Lake JR, for the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Early allograft dysfunction following liver transplantation: a definition and predictors of outcome. Transplantation. 1998;66:302-310.
22. Everhart JE, Beresford TP. Liver transplantation for alcoholic liver disease: a survey of transplantation programs in the United States. Liver Transpl Surg. 1997; 3:220-226.
23. Moss AH, Siegler M. Should alcoholics compete equally for transplantation? JAMA. 1992;265:1295-1298.
24. Benjamin M. Transplantation for alcoholic liver disease: the ethical issues. Liver Transpl Surg. 1997;3: 337-342.
25. Ubel PA. Transplantation in alcoholics: separating prognosis and responsibility from social biases. Liver Transpl Surg. 1997;3:337-342.
26. Stapleton S. Physicians, states, hospitals challenge transplant rules. American Medical News. October 19, 1998;41:1.
27. Hadorn DC. Setting health care priorities in Oregon: cost-effectiveness meets the rule of rescue. JAMA. 1991;265:2218-2225.
28. Dudley RA, Harrell FE, Smith LR, et al. Comparison of analytic models for estimating the effects of clinical factors on the cost of coronary artery bypass graft surgery. J Clin Epidemiol. 1993;46:261-271.
29. Wennberg JE, Cooper MM. The Dartmouth Atlas of Health Care in the United States. Chicago, Ill: American Hospital Publishing; 1996.